HCPs
Patients' stories
Get involved
Newly Diagnosed
Information
About ALK+ LC
Home
Who we are
What we do
Conference Booking
Early diagnosis
NICE
Shop
Contact us
Menu
Brigatinib is a 2nd generation TKI developed by Takeda. The recommended dose is 180mg taken daily. Along with Alectinib, Brigatinib is the usual first line treatment for newly diagnosed ALK-positive lung cancer patients